- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01521988
Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation (PAF CRIOBLAF)
Prevention of Atrial Fibrillation by Combined Right Isthmus Ablation and cryoBalloon Pulmonary Vein Isolation in Patients With Typical Atrial Flutter
- Background:
Atrial fibrillation is frequently associated with typical atrial flutter in clinical practice. If the radical treatment of atrial flutter by radiofrequency catheter is achieved in most cases without recurrence, it does not prevent the occurrence of atrial fibrillation that occurs in about 70% of these patients after several years of follow-up. However, the latter arrhythmia is associated with significant morbidity and mortality. The problem of atrial fibrillation occurrence after successful ablation of typical atrial flutter remains physicians primary concern in monitoring these patients.
- Objectives:
The purpose of this study is to demonstrate that the pulmonary veins isolation using balloon cryotherapy technology performed at the time of flutter ablation, significantly reduces the risk of developing atrial fibrillation in the two year period following the procedure.
- Selection Criteria:
Patients referred for ablation of typical atrial flutter with an history of at least one documented episode of atrial fibrillation (atrial flutter remaining the predominant arrhythmia)will be enrolled in the study.
- Study Methods:
This is a prospective, multicenter, randomized, 2-arms study, comparing the rate of atrial fibrillation occurrence over a two years period following either an ablation procedure of typical atrial flutter (Group 1), or a combined procedure of typical atrial flutter ablation and pulmonary veins cryoballoon isolation (Group 2). The enrollment period will be of 18 months.
Randomization will be 1:1 and will be balanced in blocks of varying size. Patients will then be regularly followed up clinically and by long-term ECG recordings.
- Evaluation Criteria:
The primary endpoint will be the recurrence of symptomatic or asymptomatic atrial fibrillation, documented by an ECG or an R-test, occurring between M3 and M24
Number of patients:
170 patients will be enrolled in the study
- Number of centers:
Four French and three German centers will participate.
- Perspective:
The demonstration of a clinical benefit in terms of atrial fibrillation risk reduction in the patient group with pulmonary vein isolation, could lead to a modification of atrial arrhythmia treatment indication.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brest, France
- CHU de Brest
-
Grenoble, France, 38000
- CHU Grenoble
-
La Rochelle, France
- CH La Rochelle
-
Marseille, France
- AP-HM - Hôpital Nord
-
Marseille, France
- Hôpital privé de Clairval
-
Nantes, France
- CHU de Nantes
-
Nantes, France
- Nouvelles Cliniques Nantaises
-
Rennes, France, 35033
- CHU de Rennes
-
Rouen, France, 76000
- University Hospital of Rouen
-
Strasbourg, France
- CHU de Strasbourg
-
Toulouse, France, 31076
- Clinique Pasteur
-
Tours, France
- CHU de Tours
-
Tours, France
- Clinique Saint Gatien
-
Trelaze, France
- Clinique Saint Joseph
-
Valenciennes, France
- Polyclinique Vauban
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with a spontaneous flutter or with a flutter recurrence when it was not considered appropriate to use a preventive treatment so far. The flutter may have been paroxysmal or may still be present.
- Patient with at least one documented episode of typical flutter defined as follows: negative F waves in the inferior territory, positive in V1 and negative in V6 lead, F wave pattern with characteristic "saw tooth" appearance and finally a heart rate comprised between 240 and 320 beats per minute.
- Patient with effective anticoagulant therapy for at least 3 weeks.
- Patient with at least one episode of AF (lasting more than 1 minute) documented on an ECG or a 24 hour Holter recording
- Patient who signed an informed consent.
- Patient with age ≥ 18 yo and ≤ 75 yo
Exclusion Criteria:
Patients with the following characteristics will be excluded:
- Contraindication to right-heart catheterization
- Contraindication to an anticoagulant treatment
- Patient for which AF is predominant (more recordings of AF than Flutter)
- Persistent AF at the time of inclusion visit
- History of mitral valve surgery
- Known disorders of blood clotting
- Cardiothyreosis
- Life expectancy < 24 months
- Less than 18 years old and pregnant ladies. As before any ablation, a pregnancy test will be done the day before or the day of the procedure
- Patient less than 18 years old
- Patient under guardianship
- Patient deprived of their liberty by a court decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Atrial flutter ablation
RF atrial flutter ablation
|
Radiofrequency ablation of Atrial flutter
|
Experimental: Atrial flutter ablation and pulmonary vein isolation
RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
|
Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence of symptomatic or asymptomatic AF as documented on an ECG or a long term Holter
Time Frame: an average of 24 months following the ablation procedure
|
Main endpoint will be the recurrence of symptomatic or asymptomatic atrial fibrillation as documented by an ECG or a R-test.
Sustained AF episodes of more than a minute will be classified depending if they are symptomatic or not.
|
an average of 24 months following the ablation procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate of typical atrial flutter
Time Frame: an average of 24 months following the ablation procedure
|
Recurrence rate of typical atrial flutter
|
an average of 24 months following the ablation procedure
|
Rate of occurrence of atypical flutter
Time Frame: an average of 24 months following the ablation procedure
|
Occurrence rate of atypical flutter defined as a continuous atrial activity (with no return to the isoelectric line)in at least one lead, whose ECG appearance of F waves is different from that of a typical flutter
|
an average of 24 months following the ablation procedure
|
Rate of occurrence of atrial tachycardia
Time Frame: an average of 24 months following the ablation procedure
|
Rate of occurrence of atrial tachycardia defined as an atrial activaty that generates a P wave with return to the isoelectric line in all leads
|
an average of 24 months following the ablation procedure
|
Rate of complications related to the ablation procedure
Time Frame: an average of 3 months after the ablation procedure
|
The following complications will be considered: Hematoma at punction site, Thromboembolic accident, Tamponnade, Phrenic nerve paralysis, Symptomatic stenosis of pulmonary vein, Atrio-ventricular block Atrioesophageal fistula |
an average of 3 months after the ablation procedure
|
Rate of major cardiovascular events
Time Frame: an average of 24 months following the ablation procedure
|
Rate of major cardiovascular events such as rehospitalization for arrhythmia, heart failure, or embolic accident
|
an average of 24 months following the ablation procedure
|
All mortality rate
Time Frame: an average of 24 months following the ablation procedure
|
All mortality rate (including sudden death and any type of death)
|
an average of 24 months following the ablation procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Frederic Anselme, MD, University Hospital, Rouen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011/089/HP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Atrial flutter ablation
-
Stiftung Institut fuer HerzinfarktforschungBoston Scientific CorporationCompleted
-
EPD Solutions, A Philips CompanyTerminated
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...TerminatedAtrial FlutterGermany
-
David B. De LurgioBoston Scientific CorporationCompletedAtrial Flutter | Cardiac Arrhythmias | Cardiac Catheter AblationUnited States
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...TerminatedAtrial FlutterGermany
-
University Hospital, RouenTerminated
-
University Hospital, GenevaUnknownRadiofrequency Ablation | Typical Atrial Flutter | Irrigated CathetersSwitzerland
-
University of LeipzigPhilips Healthcare; Heart Center Leipzig - University Hospital; Imricor Medical...Completed
-
University of RostockMedtronic; Biosense Webster, Inc.Unknown
-
University of California, San DiegoCatheter Robotics, Inc.CompletedAtrial Fibrillation | Atrial FlutterUnited States